 | Up a level |
Foster, G R; Ferenci, P; Asselah, T; Mantry, P; Dufour, Jean-François; Dufour, Jean-François; Bourlière, M; Forton, D; Maevskaya, M; Wright, D; Yoshida, E M; García-Samaniego, J; Oliveira, C; Wright, M; Warner, N; Sha, N; Quinson, A-M; Stern, J O (2016). Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. Journal of viral hepatitis, 23(3), pp. 227-231. Blackwell Science 10.1111/jvh.12485
Rüeger, S; Bochud, P-Y; Dufour, Jean-François; Müllhaupt, B; Semela, D; Heim, M H; Moradpour, D; Cerny, A; Malinverni, R; Booth, D R; Suppiah, V; George, J; Argiro, L; Halfon, P; Bourlière, M; Talal, A H; Jacobson, I M; Patin, E; Nalpas, B; Poynard, T; ... (2014). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), pp. 1605-1615. BMJ Publishing Group 10.1136/gutjnl-2014-306997
